

## COMPANY PROFILE

<b>General Profile</b> Company Name: Apogenix GmbH CEO: Dr. Thomas Hoeger Address: Im Neuenheimer Feld 584, 69120 Heidelberg, Germany Website: www.apogenix.com Origin: Spin out from DKFZ Nb of employees: 28 Annual turn over: Contact (Name, E-Mail): contact@apogenix.com	<b>Summary:</b> Apogenix is a biopharmaceutical company developing novel drugs for the treatment of malignant and inflammatory diseases. Apogenix' compounds exert their therapeutic effect by targeted modulation of signal pathways which play an important role in a variety of malignant and inflammatory diseases.  The company currently concentrates on two projects (APG101 and IL-4 blocker). After the successful phase I study on APG101 in May 2009, Apogenix is currently preparing further clinical studies in patients.
--	--

<b>Value chain</b> <input type="checkbox"/> Research <input type="checkbox"/> Preclinical development <input checked="" type="checkbox"/> Clinical development <input type="checkbox"/> Manufacturing <input type="checkbox"/> Marketing / distribution	<b>Business Model</b> <input type="checkbox"/> Pharmaceuticals <input checked="" type="checkbox"/> Biopharmaceuticals <input type="checkbox"/> Contract Organisation <input type="checkbox"/> Scientific service <input type="checkbox"/> Non-scientific service <input type="checkbox"/> Supplier	<b>Field</b> <input checked="" type="checkbox"/> Cancer <input type="checkbox"/> Infectious Diseases <input type="checkbox"/> CNS <input type="checkbox"/> Metabolism Disorders <input checked="" type="checkbox"/> Orphan Diseases <input type="checkbox"/> Auto-immune Diseases <input type="checkbox"/> Medical Devices <input type="checkbox"/> Other
--	--	---

### Technology, products and services

<input type="checkbox"/> Gene / genomics <input type="checkbox"/> Protein / proteomics <input type="checkbox"/> Chemistry <input type="checkbox"/> Vaccines <input type="checkbox"/> Tissue / cells <input type="checkbox"/> Medical devices <input type="checkbox"/> Lab equipment	<input type="checkbox"/> Screening <input type="checkbox"/> <i>in vitro</i> model <input type="checkbox"/> <i>in vivo</i> model <input type="checkbox"/> Informatics <input type="checkbox"/> Drug Delivery System <input type="checkbox"/> Imagery <input type="checkbox"/> Diagnostic <input checked="" type="checkbox"/> Drug Development <input checked="" type="checkbox"/> Drug Discovery	<b>Know-how, expertise</b> Construction of innovative biopharmaceuticals Preclinical and clinical development
---	---	---

### Product Pipeline

Preclinical	Phase I	Phase II	Phase III	MA
Alzheimer's disease				
Cancer		APG101		
MS				
Other				

### Needs and interest

<input type="checkbox"/> R&D partnership <input type="checkbox"/> Commercial alliance – co-marketing <input checked="" type="checkbox"/> Commercial development <input type="checkbox"/> Others	<b>Details</b> Apogenix is looking for strategic partners that have an interest in marketing of APG101 under an exclusive worldwide license
--	--

## COMPANY PROFILE

<b>General Profile</b> Company Name: Biorepair GmbH CEO: Martin F. Trinkner Address: 74889 Sinsheim Blumenstr. 4 Website: www.biorepair.com Origin: Nb of employees: 6 Annual turn over: ca. 1 Mio. Contact (Name, E-Mail): trinkner@Biorepair.de	<b>Summary:</b> BioRépair® founded 1997 in the innovative BioRegio Rhein Neckar close to Heidelberg. In cooperation with Universities and private institutes we develop and produce diagnostics for immunological, microbiological and parasitological detections. The fast growing market of Point of care tests and rapid diagnostic test kits is a new and important marketing field for BioRépair.
---	---

<b>Value chain</b> <input type="checkbox"/> Research <input type="checkbox"/> Preclinical development <input type="checkbox"/> Clinical development <input checked="" type="checkbox"/> Manufacturing <input checked="" type="checkbox"/> Marketing / distribution	<b>Business Model</b> <input type="checkbox"/> Pharmaceuticals <input type="checkbox"/> Biopharmaceuticals <input type="checkbox"/> Contract Organisation <input type="checkbox"/> Scientific service <input type="checkbox"/> Non-scientific service <input type="checkbox"/> Supplier	<b>Field</b> <input checked="" type="checkbox"/> Cancer <input checked="" type="checkbox"/> Infectious Diseases <input type="checkbox"/> CNS <input type="checkbox"/> Metabolism Disorders <input type="checkbox"/> Orphan Diseases <input type="checkbox"/> Auto-immune Diseases <input type="checkbox"/> Medical Devices <input type="checkbox"/> Other
---	---	---

### Technology, products and services

<input type="checkbox"/> Gene / genomics <input type="checkbox"/> Protein / proteomics <input type="checkbox"/> Chemistry <input type="checkbox"/> Vaccines <input type="checkbox"/> Tissue / cells <input type="checkbox"/> Medical devices <input type="checkbox"/> Lab equipment	<input type="checkbox"/> Screening <input type="checkbox"/> <i>in vitro</i> model <input type="checkbox"/> <i>in vivo</i> model <input type="checkbox"/> Informatics <input type="checkbox"/> Drug Delivery System <input type="checkbox"/> Imagery <input checked="" type="checkbox"/> Diagnostic <input type="checkbox"/> Drug Development <input type="checkbox"/> Drug Discovery	<b>Know-how, expertise</b> Sales and Marketing of rapid diagnostic test systems in Germany and Austria.
---	--	--

### Product Pipeline

Preclinical	Phase I	Phase II	Phase III	MA
<b>Alzheimer's disease</b>				
<b>Cancer</b>				
<b>MS</b>				
<b>Other</b>				

### Needs and interest

<input type="checkbox"/> R&D partnership <input checked="" type="checkbox"/> Commercial alliance – co-marketing <input type="checkbox"/> Commercial development <input type="checkbox"/> Others	<b>Details</b> Distribution partnership for rapid test kits and microbiological test systems.
--	--

# COMPANY PROFILE

<b>General Profile</b> Company Name: Hölle & Hüttner AG CEO: Dr. Steffen Hüttner Address: Derendinger Straße 40, 72072 Tübingen Website: www.h-net.com Origin: 1992 Nb of employees: 30 Annual turn over: 2,4 millions € Contact (Name, E-Mail): Dr. Steffen Hüttner; steffen.huettner@h-net.com	<b>Summary:</b> <b>Software development for Research, Production and Industry</b>  Technical-scientific service company with certificated process along DIN 9001:2000, specialized in consulting, process management and individual software development in Life Sciences (software development, automation, cross linking) and automotive/engineering solutions (automatic testing, sensors and measurements as well as factory data capture). IdeenScout process which improves your innovation management.
---	--

<b>Value chain</b> <input type="checkbox"/> Research <input type="checkbox"/> Preclinical development <input type="checkbox"/> Clinical development <input checked="" type="checkbox"/> Manufacturing <input type="checkbox"/> Marketing / distribution	<b>Business Model</b> <input type="checkbox"/> Pharmaceuticals <input type="checkbox"/> Biopharmaceuticals <input type="checkbox"/> Contract Organisation <input type="checkbox"/> Scientific service <input type="checkbox"/> Non-scientific service <input checked="" type="checkbox"/> Supplier	<b>Field</b> <input type="checkbox"/> Cancer <input type="checkbox"/> Infectious Diseases <input type="checkbox"/> CNS <input type="checkbox"/> Metabolism Disorders <input type="checkbox"/> Orphan Diseases <input type="checkbox"/> Auto-immune Diseases <input checked="" type="checkbox"/> Medical Devices <input type="checkbox"/> Other
--	--	--

## Technology, products and services

<input checked="" type="checkbox"/> Gene / genomics <input checked="" type="checkbox"/> Protein / proteomics <input type="checkbox"/> Chemistry <input type="checkbox"/> Vaccines <input type="checkbox"/> Tissue / cells <input type="checkbox"/> Medical devices <input checked="" type="checkbox"/> Lab equipment	<input type="checkbox"/> Screening <input type="checkbox"/> <i>in vitro</i> model <input type="checkbox"/> <i>in vivo</i> model <input checked="" type="checkbox"/> Informatics <input type="checkbox"/> Drug Delivery System <input type="checkbox"/> Imagery <input type="checkbox"/> Diagnostic <input type="checkbox"/> Drug Development <input type="checkbox"/> Drug Discovery	<b>Know-how, expertise</b> Bioinformatics & R&D instruments for automation
--	--	---

## Product Pipeline

Preclinical	Phase I	Phase II	Phase III	MA
<b>Alzheimer's disease</b>				
<b>Cancer</b>				
<b>MS</b>				
<b>Other</b>				

## Needs and interest

<input type="checkbox"/> R&D partnership <input checked="" type="checkbox"/> Commercial alliance – co-marketing <input checked="" type="checkbox"/> Commercial development <input type="checkbox"/> Others	<b>Details</b>
---	----------------

## COMPANY PROFILE

<b>General Profile</b> Company Name: Insilico Biotechnology AG CEO: Klaus Mauch Address: Nobelstr. 15 Website: www.insilico-biotechnology.com Origin: Stuttgart Nb of employees: 10 Annual turn over: 0.5 Mio EUR Contact: klaus.mauch@insilico-biotechnology.com	<b>Summary: Insilico Biotechnology</b> predicts and optimizes biotechnological processes for the chemical and healthcare industries. Since 2005, Insilico provides internationally renowned expertise and systems biotechnology services. Insilico's competitive advantage is its proven track record of producing new insights and IP for customers using its proprietary software, databases and high performance computing facilities. Insilico is a privately-owned company, located in Stuttgart, Germany.
---	---

<b>Value chain</b> <input type="checkbox"/> Research <input type="checkbox"/> Preclinical development <input type="checkbox"/> Clinical development <input type="checkbox"/> Manufacturing <input type="checkbox"/> Marketing / distribution	<b>Business Model</b> <input type="checkbox"/> Pharmaceuticals <input checked="" type="checkbox"/> Biopharmaceuticals <input checked="" type="checkbox"/> Contract Organisation <input checked="" type="checkbox"/> Scientific service <input type="checkbox"/> Non-scientific service <input type="checkbox"/> Supplier	<b>Field</b> <input type="checkbox"/> Cancer <input type="checkbox"/> Infectious Diseases <input type="checkbox"/> CNS <input type="checkbox"/> Metabolism Disorders <input type="checkbox"/> Orphan Diseases <input type="checkbox"/> Auto-immune Diseases <input type="checkbox"/> Medical Devices <input type="checkbox"/> Other
---	--	---

### Technology, products and services

<input type="checkbox"/> Gene / genomics <input type="checkbox"/> Protein / proteomics <input type="checkbox"/> Chemistry <input type="checkbox"/> Vaccines <input type="checkbox"/> Tissue / cells <input type="checkbox"/> Medical devices <input type="checkbox"/> Lab equipment	<input type="checkbox"/> Screening <input type="checkbox"/> <i>in vitro</i> model <input type="checkbox"/> <i>in vivo</i> model <input checked="" type="checkbox"/> <i>in silico</i> model <input type="checkbox"/> Drug Delivery System <input type="checkbox"/> Imagery <input type="checkbox"/> Diagnostic <input type="checkbox"/> Drug Development <input type="checkbox"/> Drug Discovery	<b>Know-how, expertise</b> By building better and innovative integrated models of complex cellular processes, Insilico sets new standards in systems biotechnology as a leading solution provider to the Life Sciences industries.
---	---	---

### Product Pipeline

Preclinical	Phase I	Phase II	Phase III	MA
Alzheimer's disease				
Cancer				
MS				
Other				

### Needs and interest

<input checked="" type="checkbox"/> R&D partnership <input checked="" type="checkbox"/> Commercial alliance – co-marketing <input type="checkbox"/> Commercial development <input type="checkbox"/> Others	<b>Details</b>
---	----------------

## COMPANY PROFILE

<b>General Profile</b> Company Name: Logopharm GmbH CEO: Dr. Uwe Schulte Address: Schloßstr. 14, 79232 March-Buchheim Website: www.logopharm.com Origin: 2005 (private) No of employees: 4 Annual turn over: Contact (Name, E-Mail): u.schulte@logopharm.com	<b>Summary</b> LOGOPHARM GmbH is engaged in proteomic target and biomarker R&D. The biotech company was established 2005 in Freiburg (Germany) by a team of scientists and business experts. It combines proprietary proteomic technologies, long-term experience in functional membrane protein analysis and innovative drug development concepts with focus on membrane proteins and protein complexes. Proprietary developments include the CompleXio technology for identification of protein-protein interactions in native tissue, microproteomic analysis with ultimate sensitivity and label-free quantitative mass spectrometry. Based on this, we offer advanced proteomic R&D services, tools and antibodies as well as technology and target-related developments.
--	---

<b>Value chain</b> <input checked="" type="checkbox"/> Research <input type="checkbox"/> Preclinical development <input type="checkbox"/> Clinical development <input type="checkbox"/> Manufacturing <input type="checkbox"/> Marketing / distribution	<b>Business Model</b> <input type="checkbox"/> Pharmaceuticals <input type="checkbox"/> Biopharmaceuticals <input type="checkbox"/> Contract Organisation <input checked="" type="checkbox"/> Scientific service <input type="checkbox"/> Non-scientific service <input checked="" type="checkbox"/> Supplier	<b>Field</b> <input type="checkbox"/> Cancer <input type="checkbox"/> Infectious Diseases <input checked="" type="checkbox"/> CNS <input type="checkbox"/> Metabolism Disorders <input type="checkbox"/> Orphan Diseases <input type="checkbox"/> Auto-immune Diseases <input type="checkbox"/> Medical Devices <input checked="" type="checkbox"/> Other
--	---	---

### Technology, products and services

<input type="checkbox"/> Gene / genomics <input checked="" type="checkbox"/> Protein / proteomics <input type="checkbox"/> Chemistry <input type="checkbox"/> Vaccines <input checked="" type="checkbox"/> Tissue / cells <input type="checkbox"/> Medical devices <input type="checkbox"/> Lab equipment	<input type="checkbox"/> Screening <input type="checkbox"/> <i>in vitro</i> model <input type="checkbox"/> <i>in vivo</i> model <input checked="" type="checkbox"/> Informatics <input type="checkbox"/> Drug Delivery System <input type="checkbox"/> Imagery <input type="checkbox"/> Diagnostic <input type="checkbox"/> Drug Development <input type="checkbox"/> Drug Discovery	<b>Know-how, expertise</b> membrane proteins, protein biochemistry antibodies molecular physiology of ion channels and receptors mass spectrometry bioinformatics
---	--	--

### Product Pipeline

Preclinical	Phase I	Phase II	Phase III	MA
<b>Alzheimer's disease</b>				
<b>Cancer</b>				
<b>MS</b>				
<b>Other</b>				

### Needs and interest

<input checked="" type="checkbox"/> R&D partnership <input type="checkbox"/> Commercial alliance – co-marketing <input type="checkbox"/> Commercial development <input checked="" type="checkbox"/> Others	<b>Details</b> We look for customers and R&D partners in the following areas: <ul style="list-style-type: none"> <li>- target discovery and characterization</li> <li>- cell line development</li> <li>- antibodies and antibody validation</li> <li>- mass spectrometry (quantification and identification)</li> </ul>
---	--

## COMPANY PROFILE

<b>General Profile</b> Company Name: PAION AG CEO: Dr. Wolfgang Söhnngen Address: Martinstr. 10-12 Website: <a href="http://www.paion.com">www.paion.com</a> Origin: Germany Nb of employees: 30 Annual turn over: 3,166 (2008) Contact (Name, E-Mail):	<b>Summary:</b>  PAION is a biopharmaceutical company headquartered in Aachen, Germany. Since the acquisition of CeNeS Pharmaceuticals, which was completed in June 2008, the company has a second site in Cambridge, UK. The company is specializing in developing and commercializing innovative drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which there is a substantial unmet medical need. PAION intends further expand its portfolio of drugs by exploiting its core expertise in identifying high-potential compounds, licensing or otherwise acquiring them and advancing them through the clinical development and regulatory approval process. PAION is listed at the Frankfurt Stock Exchange (Prime Standard Regulated Market, Stock Symbol PA8, ISIN DE000A0B65S3).
<b>Ralf Penner</b> <b>Director Investor relations &amp; Public Relations</b> <a href="mailto:r.penner@paion.com">r.penner@paion.com</a>	

<b>Value chain</b> <input checked="" type="checkbox"/> Research <input checked="" type="checkbox"/> Preclinical development <input checked="" type="checkbox"/> Clinical development <input type="checkbox"/> Manufacturing <input checked="" type="checkbox"/> Marketing / distribution	<b>Business Model</b> <input checked="" type="checkbox"/> Pharmaceuticals <input checked="" type="checkbox"/> Biopharmaceuticals <input type="checkbox"/> Contract Organisation <input checked="" type="checkbox"/> Scientific service <input type="checkbox"/> Non-scientific service <input type="checkbox"/> Supplier	<b>Field</b> <input type="checkbox"/> Cancer <input type="checkbox"/> Infectious Diseases <input checked="" type="checkbox"/> CNS <input type="checkbox"/> Metabolism Disorders <input type="checkbox"/> Orphan Diseases <input type="checkbox"/> Auto-immune Diseases <input type="checkbox"/> Medical Devices <input type="checkbox"/> Other
---	--	--

### Technology, products and services

<input type="checkbox"/> Gene / genomics <input type="checkbox"/> Protein / proteomics <input type="checkbox"/> Chemistry <input type="checkbox"/> Vaccines <input type="checkbox"/> Tissue / cells <input type="checkbox"/> Medical devices <input type="checkbox"/> Lab equipment	<input type="checkbox"/> Screening <input type="checkbox"/> <i>in vitro</i> model <input type="checkbox"/> <i>in vivo</i> model <input type="checkbox"/> Informatics <input type="checkbox"/> Drug Delivery System <input type="checkbox"/> Imagery <input type="checkbox"/> Diagnostic <input checked="" type="checkbox"/> Drug Development <input type="checkbox"/> Drug Discovery	<b>Know-how, expertise</b>
---	--	----------------------------

### Product Pipeline

Preclinical	Phase I	Phase II	Phase III	MA
Alzheimer's disease				
Cancer				
MS				
Other		4	2	

### Needs and interest

<input checked="" type="checkbox"/> R&D partnership <input checked="" type="checkbox"/> Commercial alliance – co-marketing <input type="checkbox"/> Commercial development <input type="checkbox"/> Others	<b>Details</b>
---	----------------

## COMPANY PROFILE

<b>General Profile</b> Company Name: Rentschler Biotechnologie GmbH CEO: Dr. Nikolaus F. Rentschler Address: Erwin-Rentschler-Strasse 21 Website: www.rentschler.de Origin: 1974 Nb of employees:450 Annual turn over: Contact (Name, E-Mail): Dr. Manfred Papaspyrou, manfred.papaspyrou@rentschler.de	<b>Summary:</b> Rentschler Biotechnologie GmbH, Laupheim (Germany), is an international contract manufacturer with more than 30 years of experience in the development, production and approval of biopharmaceuticals in compliance with international GMP standards (EMA / FDA). At present Rentschler Biotechnologie has nine stand-alone GMP suites with volumes of 30, 50, 250, 500 and 2,500 liters, allowing the production of material for clinical trials (phase I to III) and for market supply. In addition, Rentschler provides regulatory advice and fill and finish services.
--	---

<b>Value chain</b> <input type="checkbox"/> Research <input type="checkbox"/> Preclinical development <input type="checkbox"/> Clinical development X Manufacturing <input type="checkbox"/> Marketing / distribution	<b>Business Model</b> <input type="checkbox"/> Pharmaceuticals X Biopharmaceuticals X Contract Organisation <input type="checkbox"/> Scientific service <input type="checkbox"/> Non-scientific service <input type="checkbox"/> Supplier	<b>Field</b> <input type="checkbox"/> Cancer <input type="checkbox"/> Infectious Diseases <input type="checkbox"/> CNS <input type="checkbox"/> Metabolism Disorders <input type="checkbox"/> Orphan Diseases <input type="checkbox"/> Auto-immune Diseases <input type="checkbox"/> Medical Devices  X Other Contract manufacturing of mammalian cell derived biopharmaceuticals for all therapeutic sectors
--	---	---

### Technology, products and services

X Gene / genomics x Protein / proteomics <input type="checkbox"/> Chemistry <input type="checkbox"/> Vaccines x Tissue / cells <input type="checkbox"/> Medical devices <input type="checkbox"/> Lab equipment	<input type="checkbox"/> Screening <input type="checkbox"/> <i>in vitro</i> model <input type="checkbox"/> <i>in vivo</i> model <input type="checkbox"/> Informatics x Drug Delivery System <input type="checkbox"/> Imagery <input type="checkbox"/> Diagnostic x Drug Development <input type="checkbox"/> Drug Discovery	<b>Know-how, expertise</b> GMP-certified services: <ul style="list-style-type: none"> <li>Cell Line and Process Development</li> <li>Production of Active Pharmaceutical Ingredients (API)</li> <li>Fill and Finish</li> <li>Analytics and Quality Control</li> <li>Regulatory Affairs</li> <li>Quality Assurance</li> <li>Corporate Project Management</li> </ul>
--	---	---

### Product Pipeline : n/a

Preclinical	Phase I	Phase II	Phase III	MA
Alzheimer's disease				
Cancer				
MS				
Other				

### Needs and interest

Rentschler is seeking co-operations with pharma and biotech companies for contract manufacturing, production and registration of therapeutic proteins

## COMPANY PROFILE

<b>General Profile</b> Company Name: SymbioTec GmbH CEO: Prof. Michael Zeppezauer Address: Science Park 1, D-66123 Saarbrücken Website: www.symbiotec.biz Origin: private Nb of employees: 6 Annual turn over: Contact (Name, E-Mail): m.zeppezauer@symbiotec.biz	<b>Summary:</b> SymbioTec's goal is the development of oncolytic medicament based on the body's own proteins, histones, which are components of the innate immune system. These multifunctional proteins comprise hormonal, regulatory and protective functions, particularly cytotoxic activity against tumor cells and infectious microorganisms. Histones H1-based drugs have a broad therapeutic potential not only in hematopoietic cancers but also in solid tumors. First phase I/II clinical trial with 22 Acute Myeloid Leukemia patients proved the drug to be tolerated without side effects and showed first signs of therapeutic efficacy.
--	---

<b>Value chain</b> <input type="checkbox"/> Research <input type="checkbox"/> Preclinical development <input checked="" type="checkbox"/> Clinical development <input type="checkbox"/> Manufacturing <input type="checkbox"/> Marketing / distribution	<b>Business Model</b> <input type="checkbox"/> Pharmaceuticals <input checked="" type="checkbox"/> Biopharmaceuticals <input type="checkbox"/> Contract Organisation <input type="checkbox"/> Scientific service <input type="checkbox"/> Non-scientific service <input type="checkbox"/> Supplier	<b>Field</b> <input checked="" type="checkbox"/> Cancer <input checked="" type="checkbox"/> Infectious Diseases <input type="checkbox"/> CNS <input type="checkbox"/> Metabolism Disorders <input type="checkbox"/> Orphan Diseases <input checked="" type="checkbox"/> Auto-immune Diseases <input type="checkbox"/> Medical Devices <input type="checkbox"/> Other
--	--	--

### Technology, products and services

<input type="checkbox"/> Gene / genomics <input checked="" type="checkbox"/> Protein / proteomics <input type="checkbox"/> Chemistry <input type="checkbox"/> Vaccines <input type="checkbox"/> Tissue / cells <input type="checkbox"/> Medical devices <input type="checkbox"/> Lab equipment	<input type="checkbox"/> Screening <input type="checkbox"/> <i>in vitro</i> model <input type="checkbox"/> <i>in vivo</i> model <input type="checkbox"/> Informatics <input type="checkbox"/> Drug Delivery System <input type="checkbox"/> Imagery <input type="checkbox"/> Diagnostic <input checked="" type="checkbox"/> Drug Development <input type="checkbox"/> Drug Discovery	<b>Know-how, expertise</b> Protein analytics Down stream processing Preclinical study of own drug substance Stability study of own drug substance and product Clinical trial development
--	--	---

### Product Pipeline

Preclinical	Phase I	Phase II	Phase III	MA
<b>Alzheimer's disease</b>				
<b>Cancer</b>	<b>X AML</b>			
<b>MS</b>				
<b>Other</b>				

### Needs and interest

<input type="checkbox"/> R&D partnership <input checked="" type="checkbox"/> Commercial alliance – co-marketing <input checked="" type="checkbox"/> Commercial development <input type="checkbox"/> Others	<b>Details</b> SymbioTec is searching for partners for its further drug development such as pharmaceutical companies and investors. The company is interested in collaborations with pharmaceutical companies developing new drugs or diagnostics in areas such as cancer, antibiotics and autoimmune diseases. SymbioTec also welcomes collaboration with other academic and industrial research groups with synergistic technologies and interest in protein drug development.
---	--



